Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anterix (ATEX) Research & Development (2016 - 2025)

Anterix filings provide 13 years of Research & Development readings, the most recent being $1.1 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 1.43% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.5 million, a 34.32% decrease, with the full-year FY2025 number at $5.7 million, up 0.67% from a year prior.
  • Research & Development hit $1.1 million in Q4 2025 for Anterix, down from $1.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.2 million in Q1 2024 to a low of $767000.0 in Q1 2022.
  • Median Research & Development over the past 5 years was $1.1 million (2024), compared with a mean of $1.2 million.
  • Biggest five-year swings in Research & Development: skyrocketed 86.05% in 2023 and later crashed 51.45% in 2025.
  • Anterix's Research & Development stood at $893000.0 in 2021, then increased by 4.82% to $936000.0 in 2022, then skyrocketed by 32.26% to $1.2 million in 2023, then dropped by 9.53% to $1.1 million in 2024, then fell by 1.43% to $1.1 million in 2025.
  • The last three reported values for Research & Development were $1.1 million (Q4 2025), $1.2 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.